Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Welcome, dear readers, to
SAN FRANCISCO — Next week brings the return of the J.P. Morgan Healthcare Conference, and with it another fabled opportunity for companies in the industry to
It’s been two years since Alnylam’s founding CEO John Maraganore announced he was stepping back from the company. And in that time, he’s built up
How does John Maraganore decide which startups to get involved in? Why are longevity-minded tech bros getting involved with a controversial CRISPR scientist? And who
Can Alnylam find success with its latest cardiac treatment after tweaking the trial? And did STAT’s editorial team pull off a covert mission to get
How did advisers react to the first psychedelic therapy to go before the Food and Drug Administration? And did the American Society of Clinical Oncology
Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do you pronounce bronchiectasis? This week on “The Readout LOUD,” we
How does a drug industry lobbying group move forward after years of upheaval, including having four CEOs in four years? This week on “The Readout
On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on
What happens when a common virus jumps from birds to cows? And should we be concerned? This week on “The Readout LOUD,” STAT senior infectious